Introduction {#sec1}
============

The human placenta is a fetal organ which allows oxygen and selective nutrient uptake from the mother to the fetus, whilst acting as a discriminatory barrier. It does this by having a unique architecture, specific to human and macaque monkeys, where the placental microvessels, encased in a single layer of syncytiotrophoblast, lie bathed in maternal blood (haemomonochorial). fetal blood enters these vessels through the umbilical arteries and returns replenished via the umbilical vein. Both the thin outer syncytial lining and the fetal endothelium act as resistance in series to transport of hydrophilic solutes from maternal to fetal blood \[[@B1]\]. The feto-placental endothelial barrier integrity is therefore of critical importance to fetal growth and well-being.

The placental endothelium is continuous, with well-defined cell--cell junctions that restrict movement of large hydrophilic molecules (\>65 kDa) across the paracellular cleft \[[@B2]\]. Adherens junctions (AJs) are the major regulators of paracellular permeability in the placental capillaries with the transmembrane adhesion molecule -- vascular endothelial (VE)-cadherin being the key player \[[@B3]--[@B5]\]. Phosphorylation of VE-cadherin leads to breakage of homophilic binding, loss of anchorage to peri-junctional actin and translocation from AJ domains with accompanying increases in paracellular cleft dimensions and increased paracellular permeability \[[@B6]\]. VEGF-A, via stimulation of VEGFR2, has been shown to increase phosphorylation of VE-cadherin at Tyr-685 and Tyr-731 facilitating increased solute permeability and extravasation of cells \[[@B7]\].

The human placenta expresses the pro-angiogenic/pro-permeability VEGF-A~165~a, anti-angiogenic VEGF-A~165~b, placental growth factor (PIGF) and their receptors, VEGFR2 (KDR), VEGFR1 (Flt-1), neuropilin-1 and soluble Flt-1 (sFlt-1). There is differential expression of the growth factors during gestation and in complicated pregnancies. VEGF-A levels are highest in the first trimester during *de novo* synthesis of placental vessels \[[@B8],[@B9]\]). The *in situ* location also alters with gestation; in the last trimester VEGF-A is found predominantly in the terminal villi which house dilated fetal capillary loops involved in materno-fetal exchange \[[@B10]\]. Elevated levels of VEGF-A, loss of junctional VE-cadherin and increased vascular leakage have been reported in pregnancies complicated by maternal diabetes (\[[@B11],[@B12]\]) whilst trophoblast derived factors from pre-eclamptic placenta have been shown to diminish barrier function and alter VE-cadherin distribution *in vitro* \[[@B13]\]. The anti-angiogenic splice variant VEGF-A~165~b has been shown to be present in human term placentae as a small part of the total VEGF expression. Interestingly, there is a further down-regulation of this in pre-eclamptic placenta \[[@B14]\]. Whether this splice-variant can affect placental vascular permeability is not known.

PIGF, a homologue of VEGF \[[@B15]\], rises steadily until the second trimester of pregnancy -- a period of maximal vessel maturation and then begins to fall \[[@B16]\]. Lower PIGF levels in maternal circulation have been correlated with small-for-gestational-age babies in normal pregnancies \[[@B17],[@B18]\]. A down-regulation of syncytiotrophoblast PlGF was found in pre-eclamptic placenta \[[@B19]\]. Its function in the placenta remains to be shown experimentally. Of the various isoforms of PIGF, PIGF-2 is thought to enhance VEGF-induced permeability, whilst PIGF promotes VEGF-induced angiogenesis in some models and antagonizes in others \[[@B20],[@B15]\]).

The interplay of VEGF-A~165~a, VEGF-A~165~b and PIGF depend largely on their interactions with their receptors and co-receptors. VEGF-A~165~a is able to bind to both VEGFR1 and R2 but acts mainly via the latter \[[@B21]\]. Interestingly, neuropilin-1 can complex with VEGFR1 and R2 and has been shown to potentiate VEGFR2 activation \[[@B22]\]. VEGF-A~165~b binds to both VEGFR1 and R2 receptors but is a weaker agonist for VEGFR2 \[[@B23]\]. VEGF-A~165~b differs from VEGF-A~165~a only in the last six amino acids, the residues necessary for interaction with neuropilin-1, \[[@B24]--[@B26]\] and this lack of co-receptor binding may be behind its function as a partial receptor agonist. PlGF only binds to VEGFR1 but has been shown to propagate kinase cascades for VE-cadherin autophosphorylation \[[@B27]\]. The competitive interplay between the VEGF splice variants and PIGF in regulation of human placental endothelial junctional integrity requires elucidation.

The aim of the present study was therefore to investigate whether VEGF-A~165~a, VEGF-A~165~b and PlGF, singly or in combination can affect junctional occupancy of VE-cadherin and alter paracellular permeability of human placental/fetal endothelium. Term placenta and umbilical cord from healthy pregnancies were used for *ex vivo* placental perfusion experiments and for endothelial primary cell culture studies. Results obtained will advance understanding of the mechanisms employed by the human placenta for maintenance of the feto-placental endothelial barrier and how this could be perturbed in complicated pregnancies.

Methodology {#sec2}
===========

Placenta and umbilical cord collection {#sec2-1}
--------------------------------------

Term placentas and umbilical cords were obtained at elective caesarean section from normal pregnancies with informed patient consent and full ethical approval (REC [@B14]/SC/ 1194; NHS Heath Research Authority, U.K.), and permission from Nottingham University Hospitals, NHS Trust, U.K. The work described here has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).

All term placentas and umbilical cords were obtained from term (≥37 weeks), non-labouring women ([Table 1](#T1){ref-type="table"}) undergoing scheduled elective caesarean section delivery. Indications for caesarean section include maternal request, breech presentation, and previous caesarean section. Women with pre-existing conditions such as hypertension (\>140/90 mmHg), proteinuria, diabetes, gestational diabetes, renal and cardiac disease, and other conditions that may compromise patient health were excluded. Smokers were excluded from the study.

###### The characteristics of patients undergoing caesarean deliveries who participated in the present study, and whose data were used for further analysis

  -------------------------- ---------------
  Age (years)                29.5 ± 4.7
  BMI                        25.6 ± 2.4
  Parity                     2 \[2--3\]
  Gestational age (weeks)    40.6 ± 3.5
  Weight of placenta (g)     701.33 ± 78.5
  Sex of offspring:          
  Male                       37.5%
  Female                     62.5%
  Weight of offspring (kg)   3.3 ± 0.6
  -------------------------- ---------------

BMI, body mass index; data reported as mean ± the standard deviation (SD), median \[Interquartile range (IQR)\], or percentage of offspring.

Primary cell culture {#sec2-2}
--------------------

Human umbilical vein endothelial cell (HUVECs) were isolated from freshly delivered umbilical cords and cultured on 1% gelatin-coated flasks in complete endothelial cell medium M199 (Gibco), supplemented with 20% fetal bovine serum (FBS), heparin sodium salt (50 μg/ml), endothelial cell growth factor supplement (50 μg/ml), and penicillin/streptomycin (100 U/100 mg/ml), under humidified conditions at 37°C and 5% CO~2~/95% air. In all experiments, HUVECs were grown and used only up to the third passage.

HUVEC permeability assays {#sec2-3}
-------------------------

Polyester membrane transwell 6.5 mm^2^ inserts with a 0.4 μm pore diameter (Corning, U.K.) were coated with 1% gelatin in 0.1 M PBS. They were suspended in a 24-well cell culture plates and seeded with 5 × 10^3^ cells. Hundred microlitres of complete endothelial cell medium M199 was added to the upper compartment and 400 μl added to lower compartment to equalize hydrostatic fluid pressures. HUVECs were allowed to form a confluent monolayer before experimentation. There were four inbuilt experimental repeats (transwell assays) per experiment. The whole was repeated (×4) using HUVECS isolated from four different cords.

### Experimental design {#sec2-3-1}

Medium in the upper chamber was replaced with 100 μl of dialysed (10 kDa dialysis tubing) fluorescein isothiocyanate-conjugated bovine serum albumin (FITC-BSA, 66 kDa; Thermo Fisher) in phenol-free M199 medium at a concentration of 1 mg/ml. After a 30-min equilibration, HUVECs were exposed to a single addition of recombinant human VEGF-A~165~a (50 ng/ml), VEGF-A~165~b (50 ng/ml) or PlGF (50 ng/ml). In further experiments, VEGF-A~165~a (50 ng/ml) was followed by VEGF-A~165~b (100 ng/ml), PlGF-2 (264-PG, R&D Systems 100 ng/ml) or both VEGF-A~165~b (100 ng/ml) and PlGF-2 (100 ng/ml) in combination. Fifty microlitres of samples were collected from the lower compartment at 0, 30, 60, 90 and 120 min intervals, with the equivalent volume of fresh phenol-free M199 medium replenished after each sample collection. Samples were diluted in 50 μl of 0.1 M PBS and measured using a Thermo Fluoroskan Ascent F2 fluorescence plate reader at an emission/excitation wavelength of 495/520 nm. Concentrations of FITC--albumin in each sample were calculated via linear regression of a serial dilution series of the tracer. Total permeability of monolayers were calculated for each treatment based on the rate of solute flux (calculated in µg/min) over the first 30 min, the surface area of the monolayer, and the initial concentration difference between the upper and lower wells (1 mg/ml).

### Immunostaining {#sec2-3-2}

After experimentation, monolayers were immediately fixed in 1% PFA. Cells were permeabilized with 0.15% Triton X-100 followed by blocking with 4% normal human serum in 0.1 M PBS for 30 min at RT. Monolayers were incubated with mouse anti-human CD144 (ThermoFisher) (VE-cadherin; 5 μg/ml) overnight at 4°C and FITC-conjugated goat anti-mouse IgG (Sigma-Aldrich, 20 μg/ml) for 2 h at 37°C in the dark after requisite washes.

Extra-corporeal perfusion of the placental microvascular bed {#sec2-4}
------------------------------------------------------------

A well-established dual-perfusion procedure was employed \[[@B1],[@B2],[@B9]--[@B12]\]. To summarize, immediately after caesarean delivery, the placenta was transferred to a 37°C chamber with the umbilical cord kept clamped until cannulation to prevent loss of blood and collapse of feto-placental vessels. Within 20 min of arrival of the placenta, a vein and an artery supplying the microvascular bed of a randomly chosen intact cotyledon were each cannulated with a nasogastric (5 mm) tube to establish the fetal circulation. The placenta was inverted and the cotyledon was clamped in a Perspex chamber to isolate the lobule from the rest of the placenta. The independent maternal circulation was simulated by inserting five 5 mm nasogastric tubes into the intervillous space through the basal plate of the cotyledon, and drained through an exit tube in the Perspex chamber. Fetal and maternal circulations were connected to peristaltic pumps providing a constant 20 ml/min flow to the maternal circulation and a 5 ml/min flow to the fetal circulation, replicating the physiologic flow rates seen *in utero*. Establishment of both circulations were completed within 30 min of delivery to minimize hypoxic damage to the placenta. Perfusion was abandoned if fetal venous outflow was less than arterial inflow. From the 20 intact placenta recruited for the perfusion experiments, 15 allowed full perfusion (25% failure rate).

### Experimental design {#sec2-4-1}

A 20-min open circuit equilibration period with oxygenated Medium 199 (Sigma, Poole, U.K.), with added sodium bicarbonate (2.2 g/l), albumin (5 g/l), high molecular weight dextran (2000 *M*~r~; 8 g/l) and heparin (5000 IU/l) (final pH 7.2--7.4), was performed to reverse any post-parturition hypoxic changes \[[@B1]\]. After equilibration, fetal oxygenation was discontinued and both the maternal and foetal circulations were closed. Perfusion pressures were monitored and accepted if foetal pressure was between 40--80 mmHg and maternal pressure was between 18--20 mmHg \[[@B2]\].

Recombinant human VEGF-A~165~a (20 ng/ml), VEGF-A~165~b (20 ng/ml) or vehicle were introduced into the fetal circulation and the lobules perfused for 30 min. In reversal experiments, VEGF-A~165~a exposure was followed by a separate VEGF-A~165~b (40 ng/ml) perfusion (vehicle only acted as control) for an additional 30 min. Three different placentas were used for each experimental exposure. Tetramethylrhodamine isothiocyanate (TRITC)-conjugated dextran (76 *M*~r~; Sigma, Dorset, U.K.), 1 mg/ml) was added as a bolus into the fetal circulation for the last 10 min of all perfusions (single growth factors or sequential VEGF isoform perfusions). The lobules were then perfusion fixed with 1% paraformaldehyde in 0.1 M phosphate buffer saline (pH 7.3) for 30 min. The lobule was excised and 10 mm^3^ biopsies taken for a further immersion fixation (2 h). Biopsies were rinsed in PBS, cut into 5 mm^3^ pieces, frozen in nitrogen-cooled isopentane (Fisher Scientific UK Limited, Loughborough, U.K.) and stored at −80°C until required.

### Immunostaining {#sec2-4-2}

A minimum of six different blocks (randomly chosen) per placenta were cryo-sectioned and a minimum of six sections (5 μm thick) were taken from each block at different depths. Cryo-sections were air-dried and washed in 0.1 M PBS/BSA, before permeabilization with 0.15% Triton X-100 followed by blocking with 4% normal human serum in 0.1 M PBS for 30 min at room temperature. Sections were incubated overnight with mouse anti-human CD144 (VE-cadherin; 5 μg/ml) at 4°C and secondary antibodies as described before.

Microscopy and analysis {#sec2-5}
-----------------------

Transwell membranes and placental sections were visualized for expression of CD144 and TRITC-Dextran tracer using a Nikon LaboPhot-2 fluorescence microscope (Nikon, U.K.) and appropriate TRITC/FITC filters. Images (obtained by systematic random sampling of entire sections or membranes) from both channels were acquired using a Nikon Coolpix 995 camera (Nikon, U.K.).

Junctional integrity and tracer leakage analysis {#sec2-6}
------------------------------------------------

Micrographs were analysed using Adobe Photoshop 6.0 (Adobe systems, U.K.). A pre-determined electronic grid was placed over each image and both VE-cadherin junction integrity and evidence of TRITC-Dextran tracer leakage quantified using systematic random sampling and unbiased 'forbidden line' counting principle to ensure that no vascular profile and paracellular cleft were counted twice \[[@B11]\]. For sampling efficiency, a minimum of 200 vascular profiles were counted from images per perfused placenta; c 600 vascular profiles were analysed for each experimental condition. For HUVEC monolayers, junctional integrity was determined by counting the % of paracellular clefts showing uniform VE-cadherin staining as a continuous thin line. Gaps in cell--cell adhesion regions with VE-cadherin negative cell edges were also counted. The % of cell--cell overlap showing thicker bands of VE-cadherin localization was noted. For placental sections, the total percentage of vascular profiles showing disrupted junctional VE-cadherin (discontinuous staining or total loss) from paracellular clefts and associated tracer leakage (76 *M*~r~ Dextran-TRITC visualized as peri-vascular ablumenal fluorescent puncta or 'hotspots') was counted \[[@B11]\]. All experimental images from both HUVEC monolayers and placental sections were blinded to treatment regime before analyses.

Competitive binding ELISA {#sec2-7}
-------------------------

High-attachment 96-well ELISA plates (Corning, U.K.) were coated with recombinant Flt-1 overnight, and co-incubated with biotinylated-VEGF-A~165~b (EC75), followed by non-biotinylated-VEGF-A~165~a (0--160 nM) or PlGF (0--160 nM). Differences in VEGF binding to Flt-1 (*n*=12) were measured using streptavidin--HRP to biotin interactions, using a Thermo Fluoroskan Ascent F2 fluorescence plate reader at an absorbance wavelength of 450 nm.

Statistical analyses {#sec2-8}
--------------------

All statistical analysis was carried out using GraphPad Prism. Comparisons of means were made using one-way ANOVA with Bonferroni's *post hoc* test.

Results {#sec3}
=======

VEGF-A~165~b inhibits VEGF-A~165~a-mediated permeability in HUVECs {#sec3-1}
------------------------------------------------------------------

Incubation of HUVEC monolayers with VEGF-A~165~a resulted in an increase in FITC--albumin tracer mass leakage over time ([Figure 1](#F1){ref-type="fig"}A) compared with vehicle exposed cells. In contrast, incubation with VEGF-A~165~b in isolation showed no change in FITC--albumin tracer mass permeate compared with vehicle over time. Co-incubation of VEGF-A~165~b following 30 min of VEGF-A~165~a exposure resulted in the inhibition of VEGF-A~165~a-mediated increase in FITC--albumin tracer mass leak ([Figure 1](#F1){ref-type="fig"}A).

![VEGF-A~165~b inhibits VEGF-A~165~a-mediated permeability increase in HUVEC monolayers\
Graphs showing accumulation of FITC--albumin over time in transwell experiments (**A, B** and **C**) following exposure to VEGF-A~165~ isoforms, PIGF and vehicle only. Single VEGF additions were added at time = 0. Arrows indicate time of addition of VEGFs. (A) VEGF-A~165~a (*n*=9, red trace) showing increase in tracer mass leakage over time compared with vehicle exposed cells (black). VEGF-A~165~b (blue) shows similar leakage trace as vehicle. Addition of VEGF-A~165~b (*n*=11) following 30 min of VEGF-A~165~a exposure resulted in inhibition of this (green). (B) PlGF alone (*n*=7, magenta trace) did not increase tracer leakage, whilst co-incubation with VEGF-A~165~a (orange) shows no inhibition of its activity (red). (C) Combination of all three growth factors (*n*=5, olive) shows increased FITC--albumin solute flux, similar to VEGF-A~165~a alone. (**D**) Histograph showing the calculated permeability values of the HUVEC monolayers. VEGF-A~165~a-mediated HUVEC permeability was inhibited by addition of VEGF-A~165~b but not PlGF (*X*-axis). Co-incubation of PlGF with VEGF-A~165~b abolished the VEGF-A~165~b inhibition of VEGF-A~165~a-dependent increase in permeability (\*\*\**P*\<0.001 compared with vehicle); ND = not determined.](cs-131-cs20171252-g1){#F1}

Exposure to PlGF alone also resulted in no change in FITC--albumin tracer mass permeate with time ([Figure 1](#F1){ref-type="fig"}B). Addition of PlGF after 30 min exposure to VEGF-A~165~a did not prevent the VEGF-A~165~a-mediated effects (see [Figure 1](#F1){ref-type="fig"}B). Addition of PlGF alongside VEGF-A~165~b prevented VEGF-A~165~b-induced inhibition of VEGF-A~165~a-mediated increase in FITC--albumin tracer mass leak (see [Figure 1](#F1){ref-type="fig"}C). The calculated permeability values to FITC--albumin tracer reflected these observations, whereby exposure to VEGF-A~165~a, but not VEGF-A~165~b or PlGF significantly increased HUVEC monolayer permeability (*P*\<0.001, [Figure 1](#F1){ref-type="fig"}D). Similarly, VEGF-A~165~a-mediated permeability increase was inhibited by VEGF-A~165~b (*P*\<0.001) but not PlGF (*P*\>0.05). PlGF co-incubation with VEGF-A~165~b abolished the rescue of the latter from VEGF-A~165~a dependent increases in permeability (*P*\<0.001) ([Figure 1](#F1){ref-type="fig"}D).

VEGF-A~165~a but not VEGF-A~165~b or PlGF disrupts VE-cadherin junctions in HUVECs {#sec3-2}
----------------------------------------------------------------------------------

VE-cadherin immunostaining demonstrated the presence of positive junctional cell--cell overlap regions and thin abutting junctions with continuous VE-cadherin staining ([Figure 2](#F2){ref-type="fig"}) in control (vehicle only) experiments. Monolayers treated with VEGF-A~165~a revealed observable endothelial junctional disruption after exposure ([Figure 2](#F2){ref-type="fig"}B) with a decrease in continuous thin junctions and increase in discontinuities or total loss of VE-cadherin staining in cell--cell margins (described as gaps). This was not seen when monolayers were treated with VEGF-A~165~b ([Figure 2](#F2){ref-type="fig"}C) or PlGF ([Figure 2](#F2){ref-type="fig"}D). Quantification (systematic random sampling) of the percentage of each type of VE-cadherin positive regions ([Figure 2](#F2){ref-type="fig"}H) showed that there was a statistically significant decrease in the number of thin junctions showing continuous VE-cadherin occupancy (*P*\<0.0001) after VEGF-A~165~a exposure. VE-cadherin discontinuity within paracellular clefts increased with a significant increase in observable gaps (*P*\<0.001). No significant change in both percentage of disrupted junctions and % of continuous VE-cadherin junctions were found in VEGF-A~165~b or PlGF experiments when compared with controls (*P*\>0.05, [Figure 2](#F2){ref-type="fig"}H).

![VEGF-A~165~b inhibits VEGF-A~165~a-induced disruption of VE-cadherin junctions\
(**A**--**D**) Fluorescent micrographs showing VE-cadherin (green) immunolocalization in HUVEC monolayers treated with single additions of VEGF splice variants, PIGF or vehicle. (A) In control monolayers (vehicle treated), VE-cadherin was visualized as thick staining in cell--cell overlap regions (red arrow; thick junctions) and as continuous thin lines (yellow arrow) between cells. Some cell--cell boundaries revealed discontinuous staining (white arrow) or extensive loss of VE-cadherin staining (asterisk). Nuclei were stained with PI (red). (B) Monolayers treated with VEGF-A~165~a showed increased numbers of cell--cell junctions with loss of or discontinuous VE-cadherin staining. This increase was not seen in monolayers exposed to VEGF-A~165~b (C) or PlGF (D). (**E**--**G**) Fluorescent micrographs showing VE-cadherin immunostaining in HUVEC monolayers incubated with VEGF-A~165~a and VEGF-A~165~b (E) or PlGF (F) or both VEGF-A~165~b + PlGF (G). VE-cadherin was found to show a continuous pattern of VE-cadherin staining similar to control (see A) when co-incubated with VEGF-A~165~b (E). Disruption of VE-cadherin staining was observed in monolayers co-incubated with PlGF (F). Incubation with all three growth factors (G) resulted in persistence of discontinuous junctional profiles (asterisk, white arrows) seen for VEGF-A~165~a alone; bar = 50 µm. (**H** and **I**) Quantitative analyses of VE-cadherin junctional occupancy after exposure to growth factors. (H) 2-h exposure to VEGF-A~165~a (*n*=5) resulted in an increase in the percentage of junctions showing discontinuous or loss of junctional VE-cadherin (gaps, \*\*\**P*\<0.001) and decrease in the percentage of thin continuous VE-cadherin junctions (\*\*\*\**P*\<0.0001) when compared with vehicle only study group. Both VEGF-A~165~b (*n*=5) and PlGF (*n*=3) exposure did not change percentage junction integrity when compared with vehicle (*P*\>0.05). The number of overlapping cell--cell regions (thick) was not found to be statistically different for the different treatments. (I) VEGF-A~165~b co-incubation with VEGF-A~165~a (*n*=5) decreased the percentage of junctions showing gaps (\*\*\*\**P*\<0.0001) and increased the percentage of continuous VE-cadherin thin junctions (\*\**P*\<0.01) compared with VEGF-A~165~a. This was not seen in the PlGF co-incubation experimental group (*n*=3). However, PlGF in combination with VEGF-A~165~b (*n*=3) abolished VEGF-A~165~b inhibition of VEGF-A~165~a-mediated effects.](cs-131-cs20171252-g2){#F2}

VEGF-A~165~b prevented VEGF-A~165~a-mediated VE-cadherin junctional disruption, which was inhibited by PlGF {#sec3-3}
-----------------------------------------------------------------------------------------------------------

VEGF-A~165~b ([Figure 2](#F2){ref-type="fig"}E), but not PlGF ([Figure 2](#F2){ref-type="fig"}F), was able to prevent VEGF-A~165~a-induced disruption of VE-cadherin junctions after 2-h exposure. However, addition of PlGF in combination with VEGF-A~165~b ([Figure 2](#F2){ref-type="fig"}G) prevented the observed VEGF-A~165~b-mediated inhibition of VEGF-A~165~a-induced junctional disruption. Analysis of percentage junctional integrity ([Figure 2](#F2){ref-type="fig"}I) revealed a significant decrease in percentage of gaps after VEGF-A~165~b co-incubation (*P*\<0.0001) and an increase in percentage of thin continuous VE-cadherin junctions (*P*\<0.01). No significant changes in either percentage gap or continuous VE-cadherin AJ staining were observed after PlGF co-incubation (*P*\>0.05). However, PlGF exposure in combination with VEGF-A~165~b abolished the VEGF-A~165~b inhibition of VEGF-A~165~a-mediated effects (*P*\>0.05) (see [Figure 2](#F2){ref-type="fig"}I).

PlGF competes with VEGF-A~165~b for binding to Flt-1 {#sec3-4}
----------------------------------------------------

As the VEGF-A~165~b inhibition of VEGF-A~165~a mediated increased permeability was blocked by PlGF, which only binds VEGFR1 (flt-1), we hypothesized that this could occur if VEGF-A~165~b was inhibiting VEGF-A~165~a by signalling through VEGFR1. VEGF-A~165~a and VEGF-A~165~b compete for R1 \[[@B28]\], so we therefore determined the effect of PlGF on VEGF-A~165~b binding to VEGFR1 using an Fc-VEGFR1 chimaeric protein. Incubation of Fc-VEGFR1 with un-labelled human recombinant VEGF-A~165~b resulted in a concentration-dependent decrease in binding of biotinylated-VEGF-A~165~b (EC75). Similarly, co-incubation with un-labelled PlGF resulted in an almost identical concentration-dependent decrease in biotinylated-VEGF-A~165~b binding, with no significant difference in calculated IC~50~ between the two proteins (*P*\>0.05) (see [Figure 3](#F3){ref-type="fig"}), thus suggesting that the inhibition of VEGF-A~165~a-mediated permeability by VEGF-A~165~b could also be through its actions on VEGFR1.

![PlGF competes with VEGF-A~165~b for binding to Flt-1\
Co-incubation of Fc-VEGFR1 with un-labelled VEGF-A~165~b resulted in decreased binding of biotinylated-VEGF-A~165~b (*n*=4). PlGF co-incubation equally inhibited biotinylated-VEGF-A~165~b binding to Flt-1 binding (*n*=4) (ns = *P*\>0.05).](cs-131-cs20171252-g3){#F3}

VEGF-A~165~a-mediated increased permeability and VE-cadherin disruption are prevented by VEGF-A~165~b in the perfused human placental microvascular bed {#sec3-5}
-------------------------------------------------------------------------------------------------------------------------------------------------------

Using the more physiological dual-perfusion system, addition of growth factors to the fetal microcirculation of term placental lobules resulted in observable differences in extravasation of TRITC-dextran (75 *M*~r~) tracer (see [Figure 4](#F4){ref-type="fig"}, right panel). VEGF-A~165~a perfusions for 30 min resulted in a significant increase in percentage of vascular profiles associated with tracer leakage (71.2 ± 13.8%, [Figures 4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}) compared with control perfusions (30.2 ± 4.4%; *P*\<0.01). In contrast, perfusions of VEGF-A~165~b saw no significant increase in percentage of leaky vessels (*P*\>0.05) compared with control perfusions. Addition of VEGF-A~165~b into the closed fetal circulation after a 30 min VEGF-A~165~a perfusion period resulted in altered tracer leakage profile from that obtained with VEGF-A~165~a only perfusions. Vascular profiles (9.4 ± 1.2%) were now found to be associated with peri-vascular 'hotspots' (*P*\<0.05). This was not due to temporal recovery, as addition of vehicle only for 30 min after VEGF-A~165~a perfusion showed no significant decrease in profiles expressing hotspots (*P*\>0.05). Subsequent immunohistochemical analyses of the same sections revealed that tracer leakage matched disruption of VE-cadherin AJs (loss of VE-cadherin from paracellular clefts) ([Figure 4](#F4){ref-type="fig"}, left panel). VEGF-A~165~a-perfusion of placental microvascular beds resulted in a 49.3% decrease in vascular profiles showing VE-cadherin at paracellular clefts (*P*\<0.01), while perfusions of VEGF-A~165~b did not significantly alter VE-cadherin positive vascular profiles (86.7 ± 0.8%) compared with controls (89.3 ± 2.3%) (*P*\>0.05). Sequential addition of VEGF-A~165~b to VEGF-A~165~a perfusions resulted in a recovery of junctional integrity with 81 ± 5% of vascular profiles showing VE-cadherin at paracellular clefts (*P*\<0.05; [Figure 5](#F5){ref-type="fig"}).

![VEGF-A~165~b reverses VEGF-A~165~a-induced loss of junctional VE-cadherin and increased tracer leakage in perfused placental microvessels\
Representative fluorescent micrographs of villous biopsies taken from perfused placental microvascular beds. Left panel shows VE-cadherin staining (FITC filter) whilst right panel shows the same image under TRITC filter to visualize any peri-vascular TRITC-dextran 'hotspots'; bar = 100 µm. (**A**) Image from control perfusion (vehicle only for 30 min) showing VE-cadherin positive microvascular profiles within placental villous trees. (**B**) No peri-vascular hotspots can be seen in the same villous trees. (**C**) Image showing a dramatic reduction in VE-cadherin positive vascular profiles following a 30 min perfusion with VEGF-A~165~a. (**D**) Numerous tracer hotspots can now be seen trapped in the peri-vascular regions. (**E**) Image showing numerous VE-cadherin positive microvascular profiles in villous trees following perfusion with VEGF-A~165~b for 30 min. (**F**) Note lack of or negligible presence of tracer hotspots in these villi. (**G**) Image from placenta perfused with VEGF-A~165~a (30 min) followed by VEGF-A~165~b (30 min) and tracer. VE-cadherin positive microvascular profiles are now a predominant feature, suggesting return of VE-cadherin to junctional regions. Concomitantly, there is minimal peri-vascular tracer 'hotspots' (**H**).](cs-131-cs20171252-g4){#F4}

![Quantitative analyses of VE-cadherin junctional occupancy and tracer leakage in perfused placental microvascular beds\
(**A**) Systematic counts (from 600 vascular profiles per experimental condition) revealed that in perfused placental microvascular beds VEGF-A~165~a significantly decreased the percentage of VE-cadherin positive vascular profiles compared with VEGF-A~165~b or vehicle only (\*\*\**P*\<0.001). VEGF-A~165~b perfusion alone did not alter the % of VE-cadherin vascular profiles. In placentae where VEGF-A~165~b was added after the 30 min VEGF-~165~a perfusion, % of VE-cadherin vascular profiles was found to be similar to that of vehicle or VEGF-A~165~b perfusions. (**B**) The % of vessels showing extravasation of TRITC-dextran was significantly increased in VEGF-A~165~a study group (\*\**P*\<0.01), but not altered when placentae were perfused with VEGF-A~165~b when compared with vehicle only. VEGF-A~165~b was able to reverse VEGF-A~165~a-mediated permeability effects -- the % of vascular profiles with associated peri-vascular hotspots was highly significantly reduced compared with VEGF-A~165~a perfusions (\*\*\**P*\<0.001). \*=significant; \*\*= very significant; \*\*\*=highly significant; ns=not significant.](cs-131-cs20171252-g5){#F5}

Discussion {#sec4}
==========

These studies are the first to show that the anti-angiogenic VEGF-A~165~b does not disturb the junctional occupancy of VE-cadherin or induce paracellular tracer leakage in the human placental microvascular bed and HUVEC monolayers. Indeed, VEGF-A~165~b (at a 2-fold concentration) can block/reverse VEGF-A~165~a-mediated increases in feto-placental endothelial permeability to macromolecules (75 kDa) and loss of VE-cadherin from AJs. In these experiments, PlGF did not affect endothelial integrity, VE-cadherin localization and permeability when added singly; however, it could prevent the rescue of VEGF-A~165~a-mediated effects by VEGF-A~165~b.

The similarities between the observed induced changes in both fetal endothelial cell cultures and the more physiological and complex perfused microvascular bed are re-assuring. Placental microvessels showed a robust response to a 30 min perfusion of exogenous VEGF-A~165~a, with loss of VE-cadherin and increased vascular leak of 76 kDa dextrans. These changes were not induced when microvessels were perfused with VEGF-A~165~b; indeed this splice variant could reverse the VEGF-A~165~a-induced changes both in the perfusion model and in transwell experiments.

The monolayer permeability results are similar to those recently described in lung pulmonary endothelial cells \[[@B29]\], where VEGF-A~165~a but not VEGF-A~165~b was shown to increase monolayer permeability and decrease junctional integrity. However, they did not investigate the effect of PlGF on these cells.

The observed inability of either PlGF or VEGF-A~165~b to alter VE-cadherin occupancy and AJ integrity in human placental microvessels and fetal endothelial cells may be due to their lack of neuropilin-1 binding property \[[@B22],[@B26],[@B30]\]. Neuropilin-1 is critical for VEGF-mediated endothelial permeability in human pulmonary endothelial cells and for pulmonary vascular leaks in inducible lung-specific VEGF transgenic mice \[[@B22]\]. Stable transfection of the neuropilin-1--VEGFR2 complex in endothelial cells resulted in decreased transendothelial resistance in a dose-dependent fashion following addition of VEGF-A~165~a; this was not seen for single transfections of VEGFR2 or neuropilin-1 alone. Moreover, VEGF-A~165~b prevents the formation of neuropilin--VEGFR2 complexes by VEGF-A~165~a \[[@B31]\]. The reduction in VEGF-A~165~a-mediated enhanced permeability in our studies may be due to competitive binding of VEGF-A~165~b to the VEGFR2 receptor \[[@B25]\]. KDR occupancy by VEGF-A~165~b may be followed by internalization but not the subsequent neuropilin-1 dependent re-shuttling of KDR to the membrane surface \[[@B32]\]. This therefore would rule out further VEGF-A~165~a binding and triggering of phosphorylation events that lead to translocation of VE-cadherin from AJ domains. The recovery of junctional integrity seen in the sequential VEGF-A~165~a + VEGF-A~165~b perfusions, but not in VEGF-A~165~a + vehicle perfusions argues that VEGF-A~165~b is acting as an active signalling inhibitor. Our data allow one to hypothesize that the relative contributions of the two different VEGF-A~165~ isoforms may be an important driver behind the different feto-placental vascular permeability (and angiogenesis) observed for the different trimesters of pregnancy \[[@B9],[@B10]\].

Plasma taken from pre-eclamptic mothers has been shown to induce transient increases in permeability in amphibian models, which was blocked by VEGF-A~165~b specific neutralizing antibodies, and receptor tyrosine inhibitors at concentrations specific to VEGFR1 blockage \[[@B33]\]. This neutralizing antibody to VEGF-A~165~b was shown to prevent the inhibition of VEGF-A~165~b-mediated blockade of VEGF-A~165~a-induced migration and cytoprotection of endothelial cells \[[@B34]\] and anti-angiogenesis in peripheral vascular disease \[[@B35]\]. This suggests that the pre-eclamptic plasma not only contained physiologically active VEGF-A~165~b, but its action was incurred by altering the balance of VEGF-A~165~b, PlGF and VEGF-A~165~a, such that VEGF-A~165~a was no longer able to induce the increase in permeability, potentially by binding heterodimers of VEGF-A~165~b with either PlGF or VEGF-A~165~a. Such heterodimers are theoretically possible but have not yet been clearly demonstrated.

PIGF did not increase AJ disruption or permeability of the fetal human umbilical vein endothelial cells. PIGF-1, but not PIGF-2, has been shown to stabilize VE-cadherin junctions after activation with VEGF in bovine retinal endothelial cells and after intra-vitreal injections in mouse, during a critical window \[[@B36]\]. The isoform used here was PlGF-2, which binds heparin and is therefore able to signal through VEGFR1 with heparin, indicating that full signalling does require the heparin binding domains. The PlGF-mediated abolition of VEGF-A~165~b induced reversal of VEGF-A~165~a-induced permeability was surprising. However, recent studies by Ganta et al. \[[@B37]\] have shown that VEGF-A~165~b inhibits VEGF-A~165~a-mediated signalling in adipose endothelial cells through inhibiting VEGFR1-mediated activation of the signal transducer and activator of transcription 3 (STAT3) pathway. It is therefore possible that VEGF-A~165~b binds VEGFR1, inhibiting STAT3 signalling. When PlGF binds VEGFR1, even if it does not inhibit STAT3 signalling (or stimulate it), it prevents VEGF-A~165~b from inhibiting it, so VEGF-A~165~a would then be at liberty to increase permeability. There are currently no studies identifying whether PlGF signals through STAT3 or how it affects VEGF-A~165~a-mediated STAT3 signalling, but it would appear that such studies are warranted.

In our HUVEC studies, when PlGF was added in combination with VEGF-A~165~b, there was an abolition of the VEGF-A~165~b-induced reversal of VEGF-A~165~a-induced permeability. Whilst it is well known that VEGF-A~165~a and PIGF can compete for VEGF-R1 binding \[[@B38]\], in the present study we have also shown that incubation of Fc-VEGFR1 with un-labelled PlGF resulted in a concentration-dependent decrease in biotinylated-VEGF-A~165~b binding. Thus, addition of PIGF may have resulted in release of both splice variants. The excess VEGF-A~165~a would then be at liberty to increase permeability via KDR--neuropilin signalling. Hetero-dimerization of PIGF with VEGF-A~165~b could further assist VEGF-A~165~a activity. Further studies are needed to understand the complex interplay between VEGF-A/PIGF and their receptors/co-receptors. Elucidation of the multiple signalling pathways, including whether/where the VEGFR1-linked angiogenic signalling pathway interacts with the VEGFR2-linked phosphorylation events that lead to disruption of VE-cadherin junctions is needed to understand how placental/fetal barrier function is regulated.

In summary, we have shown that VEGF-A~165~b is able to inhibit vascular permeability induced by VEGF-A~165~a *in vitro*, and in human placenta *ex vivo*, and that this is interfered with by placental growth factor. These results suggests that alterations in the ratio of these growth factors during normal placental development and in complicated pregnancies such as pre-eclampsia and diabetes would influence VE-cadherin clustering in fetal vessels and therefore placental barrier function, given that both the fetal endothelium and the syncytiotrophoblast act as resistance in series to materno-fetal hydrophilic solute transport.

Clinical perspectives {#sec5}
=====================

-   The anti-angiogenic VEGF-A~165~b isoform does not increase permeability in human placental microvessels or fetal endothelial cells.

-   VEGF-A~165~b isoform can interrupt VEGF-A~165~a-induced permeability of feto-placental vessels.

-   The interplay of the VEGF-A~165~ isoforms with PIGF suggests that the ratio of these three factors may be important in determining the placental endothelial barrier and therefore fetal well-being in normal and complicated pregnancies.
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AJ

:   adherens junction

FITC-BSA

:   fluorescein isothiocyanate-conjugated bovine serum albumin

Flt-1

:   Fms-like tyrosine kinase

HUVEC

:   human umbilical vascular endothelial cell

KDR

:   kinase insert domain receptor
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:   placental growth factor
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sFlt-1

:   soluble fms-like tyrosine kinase

STAT3

:   signal transducer and activator of transcription 3

TRITC

:   tetramethylrhodamine isothiocyanate

VE-cadherin

:   vascular endothelial-cadherin

VEGF

:   vascular endothelial growth factor

VEGFR1

:   vascular endothelial growth factor receptor-1

VEGFR2

:   vascular endothelial growth factor receptor-2
